Early Detection Is a Personal Choice

For many, healthcare begins when something feels wrong — a nagging pain, unusual fatigue, or symptoms that can no longer be ignored. That moment of concern leads to appointments, tests, referrals, and eventually, a diagnosis. By then, the body may have already crossed a threshold. The opportunity for prevention has passed.

“We’ve trained ourselves to respond to crisis instead of investing in clarity,” said David Medvedeff, CEO of Radence. “But it doesn’t have to be that way.”

Today, the landscape of healthcare is shifting. Groundbreaking advancements in science and technology are making it possible to detect risks and uncover disease long before symptoms arise. This is more than just progress. It’s an invitation to take ownership of personal health in a way that is proactive, precise and deeply empowering.

Conventional healthcare was built to intervene after illness begins. Even individuals with access to premium services often find themselves navigating a fragmented system of multiple specialists, disjointed testing, and a lack of holistic insight to optimize wellness.

“What people want isn’t more information,” Medvedeff said. “They want precise data-driven actions. They want to trust that they’re seeing the full picture and that nothing important is being missed.”

Discerning individuals expect more. There is a desire to understand and protect what matters most before it’s at risk. That’s where comprehensive early detection and prevention enters the conversation.

The real power of early detection lies in what it makes visible, revealing the silent chronic illnesses that often progress unnoticed including cancer, cardiovascular, metabolic, and neurological diseases. Radence expertly develops best-in-class proprietary protocols for advanced testing, such as organ-specific MRIs, Whole Genome Sequencing, multi-cancer screening, and advanced cardiac imaging to provide an unprecedented and personalized view into the body’s future risks.

“It’s not a contest to see how many biomarkers we can tally, that’s a fool’s game,” Medvedeff said. “It’s about selecting the right tests, the ones grounded in science, personalized to each member’s ROI, that can reveal meaningful insight we can do something about.”

This level of precision allows for focused, evidence-based decisions. It eliminates guesswork and brings clarity.

When approached with purpose, early detection data is not about overwhelming people with numbers and potentially creating unnecessary anxiety. It’s about providing actionable insights. A well-designed early detection and prevention strategy offers more than information. It delivers confidence. “Let’s face it, if you have cancer or cardiovascular disease you will know about it one day. The question is do you want to know about it early, when it is highly treatable, or would you rather wait and see if conventional medicine can do something heroic for you. Either way, you will know about it,” Medvedeff said.

Early detection provides the answer. And it does so in a way that allows for data-driven decision making early enough to have an impact on the future. This is an advancement in the past few years that is only just coming to light, one that Radence members can have now and will eventually change the face of medical care for everyone.

Trust is the cornerstone of any healthcare relationship. It is built on integrity. Offering a higher standard of care means consistently aligning science, service, and empathy.

“True luxury in healthcare is knowing that your care is grounded in science, delivered with accuracy, and tailored to you as a whole person,” Medvedeff said.

Radence’s multimodal approach integrates precision medicine with thoughtful, personalized guidance in partnership with our members’ trusted physicians and concierge doctors. It ensures that no result is left unexamined, and that each next step is considered with care and in context of one’s personal and family health history and concerns.

When precision medicine and advanced early detection meet highly personalized, compassionate care, the result is a healthcare experience rooted in science, wisdom and excellence. This is the Radence Standard of Care: anticipatory, personalized, and scientifically sound.

“The future of healthcare is here,” Medvedeff said. “And it’s time we hold our health to the same higher standard we hold for every other aspect of our lives. Now is the time to embrace clarity, pursue insight, and choose prevention. Because health, at its best, is not only about avoiding illness. It’s about creating the conditions to add more life to every year. ”

It’s health.

Most investors ask: Will my assets last as long as I live?

Far fewer ask: How many of those years will I remain cognitively sharp, physically capable, and able to live as I choose?

That distinction matters.

A long life lived in poor health is not only emotionally costly. It is financially destabilizing. Late-stage illness can quickly erode even the most carefully constructed wealth strategy.

Chronic disease now drives 90% of healthcare costs in the United States. Yet many of these conditions develop silently for years before symptoms appear. By the time traditional medicine intervenes, options are often narrower and more expensive.

This is where medicine is changing.

Advances in genomics, imaging, and molecular biomarkers now allow clinicians to detect disease signals earlier than ever before. Instead of waiting for decline, we can establish baselines, monitor subtle shifts, and intercept risk before it alters the trajectory of our healthspan, which is the number of years a person remains cognitively sharp, physically capable, and able to live independently.

One clear example of how scientific advancement is changing care is Alzheimer’s disease. For years, it was widely viewed as an inevitable diagnosis identified only after meaningful cognitive decline. Today, that assumption is being challenged. Emerging diagnostics and therapies suggest that earlier identification and intervention can meaningfully slow progression in appropriate patients.

The approach increasingly resembles the NFL’s concussion protocol. You establish a precise baseline using imaging, blood-based biomarkers, and cognitive assessment. You monitor carefully over time. And at the first sign of deviation from baseline, you intervene.

That shift is significant. When disease is identified early in its course, certain therapies have demonstrated the ability to slow progression. Slowing progression does not eliminate disease. But it can preserve cognitive clarity and independence for longer. From a financial planning standpoint, the preservation of decision-making capacity and autonomy can materially affect long-term care costs, estate timing, and intergenerational planning.

Preserving healthy, functional years does more than improve quality of life. It materially alters long-term care costs, estate outcomes, and the preservation of intergenerational wealth.

At Radence, we integrate advanced diagnostics, continuous monitoring, and personalized care coordination into a structured, science-driven model. Our goal is not simply to extend lifespan. It is to bring clarity to risk, offer control, and help preserve more healthy, functional years. It is to help members spend more of their years in peak health.

Investors expect their advisors to anticipate financial risk before it appears on a balance sheet.

The most forward-thinking individuals are beginning to treat health as a measurable, managed variable within long-term strategy.

If you’d like to learn how Radence approaches early detection and precision prevention, we welcome a private conversation.

Schedule a Discovery Call